A Phase I––II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

Author： Lassen Ulrik   Jensen Lars Henrik   Sorensen Morten   Rohrberg Kristoffer S.   Ujmajuridze Zaza   Jakobsen Anders  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.3, 2011-04, pp. : 448-454

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I-II Trial of Fixed-dose Carboplatin and Escalating Paclitaxel in Advanced Ovarian Cancer

By Bolis G.   Scarfone G.   Zanaboni F.   Villa A.   Presti M.   Melpignano M.   Ferraris C.   Tateo S.   Guarnerio P.   Gentile A.   Parazzini F.  

European Journal of Cancer, Vol. 33, Iss. 4, 1997-04 ,pp. : 592-595

Elsevier

Access to resources Recommend Favorite

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

By Sausville Edward   LoRusso Patricia   Carducci Michael   Carter Judith   Quinn Mary   Malburg Lisa   Azad Nilofer   Cosgrove David   Knight Richard   Barker Peter   Zabludoff Sonya   Agbo Felix   Oakes Patricia   Senderowicz Adrian  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 539-549

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors

By Fury Matthew   Solit David   Su Yungpo   Rosen Neal   Sirotnak F.   Smith Robert   Azzoli Christopher   Gomez Jorge   Miller Vincent   Kris Mark   Pizzo Barbara   Henry Roxanne   Pfister David   Rizvi Naiyer  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 467-475

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma

By Carneiro Benedito A.   Brand Randall E.   Fine Elita   Knop Richard H.   Khandekar Janardan D.   Uhlig William   Locker Gershon Y.  

Cancer Investigation, Vol. 25, Iss. 5, 2007-07 ,pp. : 366-371

Informa Healthcare

Access to resources Recommend Favorite